IP Library Granted Patent US 9,725,431
Granted Patent B2
US 9,725,431 · App. 14/020,196 · Granted Aug 8, 2017

Oligomer-tricyclic conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,725,431
App. No.
14/020,196
Granted
Aug 8, 2017
Kind
B2
Abstract

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer.

Claims (13)

1. A method of treatment, comprising administering a stable conjugate selected from:

wherein n is an integer from 1 to 30, to a patient in need thereof;

wherein the compound is administered for sedative, hypnotic, anti-anxiety, tranquilizing, anti convulsant, muscle relaxant, anti-depressant, or analgesic effect.

2. The method of claim 1 , wherein n is an integer from 1 to 10.

3. The method of claim 2 , wherein the stable conjugate has the structure:

4. The method of claim 3 , wherein n is 3, 5, 6, or 7.

5. The method of claim 2 , wherein the stable conjugate has the structure:

6. The method of claim 1 , wherein the stable conjugate is administered to treat pain.

7. The method of claim 6 , wherein the stable conjugate is administered to treat neuropathic pain.

8. The method of claim 6 , wherein the stable conjugate is administered to treat visceral pain.

9. A method of claim 1 , wherein the stable conjugate is administered as a pharmaceutical composition comprising the stable conjugate, and optionally, a pharmaceutically acceptable excipient.

10. The method of claim 9 , wherein the pharmaceutical composition is suitable for oral administration.

11. The method of claim 1 , wherein the stable conjugate is administered as a unit dosage form.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 31838, FRAME 0343 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036876/0138 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
SECURITY AGREEMENT Recorded Dec 18, 2013
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 031838/0343 →